BS_Z45HD492
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 14.224704336399475
- age_years
- 2.066
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.637
- G2M_CHECKPOINT+0.559
- MYC_TARGETS_V1+0.474
- MYC_TARGETS_V2+0.326
- SPERMATOGENESIS+0.325
- DNA_REPAIR+0.304
- PANCREAS_BETA_CELLS+0.260
- MITOTIC_SPINDLE+0.146
- HEME_METABOLISM-0.039
- WNT_BETA_CATENIN_SIGNALING-0.048
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.554
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- CHOLESTEROL_HOMEOSTASIS-0.484
- NOTCH_SIGNALING-0.476
- INFLAMMATORY_RESPONSE-0.469
- IL6_JAK_STAT3_SIGNALING-0.452
- UV_RESPONSE_DN-0.420
- MYOGENESIS-0.414
- PROTEIN_SECRETION-0.414
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_09Z7TC35 | medulloblastoma | — | 0.982 |
| 2 | BS_E3BAT4C1 | medulloblastoma | — | 0.975 |
| 3 | BS_TYAYZ9ZW | medulloblastoma | — | 0.973 |
| 4 | BS_SKGJ5SY9 | medulloblastoma | — | 0.971 |
| 5 | BS_EFE4YEK3 | medulloblastoma | — | 0.964 |
| 6 | BS_V9HVBBDW | medulloblastoma | — | 0.964 |
| 7 | BS_QT3NZ2YZ | Embryonal tumors | — | 0.961 |
| 8 | BS_Y8D1F5WW | medulloblastoma | — | 0.958 |
| 9 | BS_G00FHF3Q | medulloblastoma | — | 0.958 |
| 10 | BS_9PB3XH5D | medulloblastoma | — | 0.956 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.637 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.559 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.474 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.326 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.325 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.304 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.146 | Inavolisib | — uncovered |